Abstract: The objective of the present invention is to provide a novel bacteriophage useful for treating bacterial endophthalmitis and a therapeutic agent for bacterial endophthalmitis comprising the novel bacteriophage. The therapeutic agent for bacterial endophthalmitis according to the present invention is characterized in comprising 1 or more bacteriophages selected from the group essentially consisting of Myoviridae Spounavirinae phiEF7H (accession number: NITE BP-02886), Myoviridae Spounavirinae phiEF19G (accession number: NITE BP-02887), Myoviridae Spounavirinae phiEF14H1 (accession number: NITE BP-02888), and mutants thereof.

Abstract: There are provided a method and a kit for evaluating allergen inactivators, the method and kit making it possible to carry out a precise and reproducible evaluation irrespective of the type of test drug, or the type of accompanying components thereof, that is subject to the evaluation.

Abstract: The present invention is intended to provide a lactic acid bacterium-containing composition that is effective for suppression of the onset of allergies. More specifically, the present invention relates to a composition comprising lactic acid bacteria belonging to Lactobacillus animalis, wherein the composition is provided in the form of, for example, a food or beverage composition, a pharmaceutical composition, a feed composition, a sanitary composition or the like. Furthermore, the present invention provides a method for preventing the onset of allergies.

Abstract: The objective of the present invention is to provide a novel bacteriophage useful for treating bacterial endophthalmitis and a therapeutic agent for bacterial endophthalmitis comprising the novel bacteriophage. The therapeutic agent for bacterial endophthalmitis according to the present invention is characterized in comprising 1 or more bacteriophages selected from the group essentially consisting of Myoviridae Spounavirinae phiEF7H (accession number: NITE BP-02886), Myoviridae Spounavirinae phiEF19G (accession number: NITE BP-02887), Myoviridae Spounavirinae phiEF14H1 (accession number: NITE BP-02888), and mutants thereof.

Abstract: Provided is a method for determining the genuineness or spuriousness of a pharmaceutical composition for oral administration, comprising irradiating a pharmaceutical composition for oral administration with infrared light, the pharmaceutical composition for oral administration being marked with a mark including an edible substance which is visually recognizable under white light irradiation as well as under infrared irradiation and a mark including an edible substance which is visually recognizable under white light irradiation and is not visually recognizable under infrared irradiation, and determining whether a visually recognizable mark visually recognized on the pharmaceutical composition for oral administration irradiated with the infrared light and a prepared reference mark match.